New hope for lymphoma patients? early trial combines targeted drug with standard chemo
NCT ID NCT04850495
First seen Nov 24, 2025 · Last updated May 17, 2026 · Updated 21 times
Summary
This early-phase trial is testing a new drug, zanubrutinib, added to a standard chemotherapy cocktail (R-PolaCHP) for people newly diagnosed with diffuse large B-cell lymphoma. The main goal is to find the safest dose and see how well the combination works. About 38 adults with certain types of lymphoma are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
MUSC
Charleston, South Carolina, 29425, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.